Antibody Evasion by the P.1 Strain of SARS-CoV-2

Terminating the SARS-CoV-2 pandemic relies upon pan-global vaccination. Current vaccines elicit neutralizing antibody responses to the virus spike derived from early isolates. However, new strains have emerged with multiple mutations, including P.1 from Brazil, B.1.351 from South Africa, and B.1.1.7 from the UK (12, 10, and 9 changes in the spike, respectively). All have mutations in the ACE2 binding site, with P.1 and B.1.351 having a virtually identical triplet (E484K, K417N/T, and N501Y), which we show confer similar increased affinity for ACE2. We show that, surprisingly, P.1 is significantly less resistant to naturally acquired or vaccine-induced antibody responses than B.1.351, suggesting that changes outside the receptor-binding domain (RBD) impact neutralization. Monoclonal antibody (mAb) 222 neutralizes all three variants despite interacting with two of the ACE2-binding site mutations. We explain this through structural analysis and use the 222 light chain to largely restore neutralization potency to a major class of public antibodies.

Citing Articles

Direct current electrical fields inhibit cancer cell motility in microchannel confinements.

Naggay B, Farahani S, Gao X, Holle A, Kemkemer R Sci Rep. 2025; 15(1):4605.

PMID: 39920207 PMC: 11806051. DOI: 10.1038/s41598-025-87737-7.

Inferring effects of mutations on SARS-CoV-2 transmission from genomic surveillance data.

Lee B, Quadeer A, Sohail M, Finney E, Ahmed S, McKay M Nat Commun. 2025; 16(1):441.

PMID: 39774959 PMC: 11707167. DOI: 10.1038/s41467-024-55593-0.

Structural insights into hybridoma-derived neutralizing monoclonal antibodies against Omicron BA.5 and XBB.1.16 variants of SARS-CoV-2.

Hu H, Leng C, Shu Y, Peng L, Wu F, Liu J J Virol. 2025; 99(2):e0130724.

PMID: 39772622 PMC: 11852929. DOI: 10.1128/jvi.01307-24.

Strategies Used by SARS-CoV-2 to Evade the Innate Immune System in an Evolutionary Perspective.

Fan H, Tian M, Liu S, Ye C, Li Z, Wu K Pathogens. 2025; 13(12.

PMID: 39770376 PMC: 11677916. DOI: 10.3390/pathogens13121117.

SARS-CoV-2 strains and clinical profiles of COVID-19 patients in a Southern Brazil hospital.

Fam B, Cadore N, Sbruzzi R, Feira M, Giudicelli G, de Almeida L Front Immunol. 2025; 15:1444620.

PMID: 39744633 PMC: 11688617. DOI: 10.3389/fimmu.2024.1444620.

References

Seemann T, Lane C, Sherry N, Duchene S, Goncalves da Silva A, Caly L . Tracking the COVID-19 pandemic in Australia using genomics. Nat Commun. 2020; 11(1):4376. PMC: 7462846. DOI: 10.1038/s41467-020-18314-x. View

Wibmer C, Ayres F, Hermanus T, Madzivhandila M, Kgagudi P, Oosthuysen B . SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat Med. 2021; 27(4):622-625. DOI: 10.1038/s41591-021-01285-x. View

Tarke A, Sidney J, Methot N, Yu E, Zhang Y, Dan J . Impact of SARS-CoV-2 variants on the total CD4 and CD8 T cell reactivity in infected or vaccinated individuals. Cell Rep Med. 2021; 2(7):100355. PMC: 8249675. DOI: 10.1016/j.xcrm.2021.100355. View

Cerutti G, Guo Y, Zhou T, Gorman J, Lee M, Rapp M . Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite. Cell Host Microbe. 2021; 29(5):819-833.e7. PMC: 7953435. DOI: 10.1016/j.chom.2021.03.005. View

Baden L, El Sahly H, Essink B, Kotloff K, Frey S, Novak R . Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2020; 384(5):403-416. PMC: 7787219. DOI: 10.1056/NEJMoa2035389. View

Supasa P, Zhou D, Dejnirattisai W, Liu C, Mentzer A, Ginn H . Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. Cell. 2021; 184(8):2201-2211.e7. PMC: 7891044. DOI: 10.1016/j.cell.2021.02.033. View

Starr T, Greaney A, Dingens A, Bloom J . Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016. Cell Rep Med. 2021; 2(4):100255. PMC: 8020059. DOI: 10.1016/j.xcrm.2021.100255. View

Kemp S, Collier D, Datir R, Ferreira I, Gayed S, Jahun A . SARS-CoV-2 evolution during treatment of chronic infection. Nature. 2021; 592(7853):277-282. PMC: 7610568. DOI: 10.1038/s41586-021-03291-y. View

Donthu N, Gustafsson A . Effects of COVID-19 on business and research. J Bus Res. 2020; 117:284-289. PMC: 7280091. DOI: 10.1016/j.jbusres.2020.06.008. View

10.

Winter G, Waterman D, Parkhurst J, Brewster A, Gildea R, Gerstel M . DIALS: implementation and evaluation of a new integration package. Acta Crystallogr D Struct Biol. 2018; 74(Pt 2):85-97. PMC: 5947772. DOI: 10.1107/S2059798317017235. View

11.

Wang Q, Zhang Y, Wu L, Niu S, Song C, Zhang Z . Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2. Cell. 2020; 181(4):894-904.e9. PMC: 7144619. DOI: 10.1016/j.cell.2020.03.045. View

12.

Yuan M, Liu H, Wu N, Lee C, Zhu X, Zhao F . Structural basis of a shared antibody response to SARS-CoV-2. Science. 2020; 369(6507):1119-1123. PMC: 7402627. DOI: 10.1126/science.abd2321. View

13.

Domingo E, Perales C . Viral quasispecies. PLoS Genet. 2019; 15(10):e1008271. PMC: 6797082. DOI: 10.1371/journal.pgen.1008271. View

14.

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H . Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395(10224):565-574. PMC: 7159086. DOI: 10.1016/S0140-6736(20)30251-8. View

15.

Caly L, Druce J, Roberts J, Bond K, Tran T, Kostecki R . Isolation and rapid sharing of the 2019 novel coronavirus (SARS-CoV-2) from the first patient diagnosed with COVID-19 in Australia. Med J Aust. 2020; 212(10):459-462. PMC: 7228321. DOI: 10.5694/mja2.50569. View

16.

Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020; 397(10269):99-111. PMC: 7723445. DOI: 10.1016/S0140-6736(20)32661-1. View

17.

Volz E, Hill V, McCrone J, Price A, Jorgensen D, OToole A . Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity. Cell. 2020; 184(1):64-75.e11. PMC: 7674007. DOI: 10.1016/j.cell.2020.11.020. View

18.

Aricescu A, Lu W, Jones E . A time- and cost-efficient system for high-level protein production in mammalian cells. Acta Crystallogr D Biol Crystallogr. 2006; 62(Pt 10):1243-50. DOI: 10.1107/S0907444906029799. View

19.

Pinto D, Park Y, Beltramello M, Walls A, Tortorici M, Bianchi S . Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 2020; 583(7815):290-295. DOI: 10.1038/s41586-020-2349-y. View

20.

Walls A, Park Y, Tortorici M, Wall A, McGuire A, Veesler D . Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020; 181(2):281-292.e6. PMC: 7102599. DOI: 10.1016/j.cell.2020.02.058. View